(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide is an experimental small molecule inhibitor of dipeptidyl peptidase IV (DPP-IV). It was identified and characterized by researchers at Merck Research Laboratories as part of a series of tetrahydroisoquinoline-based inhibitors intended for the treatment of type 2 diabetes mellitus. The compound acts by binding to the active site of the DPP-IV enzyme, thereby preventing the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are essential for glucose homeostasis. While it has been used extensively in structural biology studies (e.g., PDB ID 1X70) to understand the molecular interactions within the DPP-IV binding pocket, it does not appear to have advanced into clinical trials or received a formal international nonproprietary name (INN).

Other names

DB04578DB-04578DB 04578DPP-IV Inhibitor 1Compound 2Compound2Compound-2